Aclaris Therapeutics Mourns the Passing of Board Member Richard A. Bierly
November 09 2017 - 4:05PM
Aclaris Therapeutics, Inc. (Nasdaq:ACRS), a dermatologist-led,
biopharmaceutical company focused on identifying, developing and
commercializing innovative and differentiated therapies to address
significant unmet needs in medical and aesthetic dermatology, today
announced with great sorrow that Rick Bierly, a valued member of
the company's board of directors and chairman of the audit
committee of the board, has passed away.
“Rick was a highly appreciated board member with comprehensive
medical and business experience, and we are deeply saddened by his
passing. He was an inspiring leader and friend. He brought
great value and warmth to our company and he will be greatly
missed,” said Aclaris’ President and CEO Dr. Neal Walker.
“Rick was appointed to Aclaris Therapeutics’ board of directors
on October 2015, and he made valuable contributions to the Board
during his tenure. Our thoughts are with Rick’s family.”
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. is a dermatologist-led
biopharmaceutical company focused on identifying, developing and
commercializing innovative and differentiated therapies to address
significant unmet needs in medical and aesthetic dermatology.
Aclaris is focused on large, underserved market segments with no
FDA-approved medications or where treatment gaps exist.
Aclaris is based in Malvern, Pennsylvania and more information can
be found by visiting the Aclaris website at www.aclaristx.com.
Contact: Aclaris Contact Michael Tung, M.D.
Investor Relations 484-329-2140 mtung@aclaristx.com
Aclaris Therapeutics (NASDAQ:ACRS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aclaris Therapeutics (NASDAQ:ACRS)
Historical Stock Chart
From Apr 2023 to Apr 2024